Brought to you by 
G1 and Genentech enter small cell lung cancer trial collaboration
18 Oct 2021
Executive Summary
G1 Therapeutics Inc. and Genentech Inc. entered into a trial collaboration to investigate the combination of G1’s trilaciclib (G1T28) with Genentech’s Tecentriq (atezolizumab) for patients with small cell lung cancer receiving chemotherapy.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
G1 and Genentech enter small cell lung cancer trial collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice